Kras inhibitors
OwnerBrian Edward FINK, Pravin S. SHIRUDE +11inventors
InventorsBrian Edward FINK, Pravin S. SHIRUDE, Amit Kumar CHATTOPADHYAY, Laxmi Narayan NANDA, Vishweshwaraiah BALIGAR, Balaji SESHADRI, T.G. Murali DHAR, Li-Qiang SUN, Zhizhen Barbara ZHENG, Manoranjan PANDA, Maximilian David PALKOWITZ, Sirish Kaushik LAKKARAJU, Moloy BANERJEE
Life of this patent
Estimating the term…
Abstract
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
Claims26
A compound of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- Y is O or SO2;
- R1 is hydrogen, halo, ethynyl or ethyl;
- R1′ is hydrogen, halo, or C1-3 alkyl;
- R1″ is selected from hydrogen, C2-3alkenyl, C1-3 alkyl, C2-3 alkynyl, halo, and hydroxy;
- R2 is hydrogen;
- R3 is halo;
- R4 and R5 are the same or different and each is hydrogen, C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, or C1-4 haloalkyl;
- R20 is selected from hydrogen and hydroxyC1-4alkyl;
- R6 is C1-6 alkyl optionally substituted with one or more deuterium atoms;
- C3-6 cycloalkyl optionally substituted with C1-C3alkoxy, C1-C3alkoxyC1-6 alkyl, amino, or cyanoethynyl;
- hydroxyC1-6 alkyl;
- haloC1-6 alkyl;
- hydroxy-haloC1-6 alkyl;
- methylsulfonylC1-C6alkyl;
- or —(CH2)n-A;
- wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-10 heterocycloalkyl, aryl, heteroaryl, spiro structures of any of these rings, and bicyclic structures of any of these rings, and n is 0, 1, 2, or 3;
- wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, hydroxy, halo, cyano, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, and methylsulfonyl;
- and
- R7 and R8 are the same or different and each is hydrogen, hydroxy, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.
-6. (canceled)
A compound of formula (II):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is ethynyl or ethyl;
- R1′ is hydrogen or halo;
- R1″ is selected from hydrogen, C2-3alkenyl, C1-3 alkyl, C2-3 alkynyl, halo, and hydroxy;
- R2 is hydrogen;
- R3 is halo;
- R4, R5, R4′, and R5′ are the same or different and each is hydrogen, haloC1-4 alkyl, C1-4 alkyl, hydroxy, or hydroxyC1-4alkyl, or, R4′ and R5′, together with the atom to which they are attached, form a five-membered heterocycloalkyl ring optionally substituted with oxo;
- R6 is C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, hydroxy-haloC1-6 alkyl, methylsulfonylC1-C6alkyl, or —(CH2)n-A;
- wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-7 heterocycloalkyl, spiro structures of either of these rings, and bicyclic structures of either of these rings, and n is 0, 1, or 2;
- wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, hydroxy, halo, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, and methylsulfonyl;
- and
- R7 and R8 are the same or different and each is hydrogen, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.
-12. (canceled)
A compound of formula (III):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is ethynyl or ethyl;
- R1′ is hydrogen or halo;
- R1″ is selected from hydrogen, C2-3alkenyl, C1-3 alkyl, C2-3 alkynyl, halo, and hydroxy;
- R2 is hydrogen;
- R3 is halo;
- R6 is C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, hydroxy-haloC1-6 alkyl, methylsulfonylC1-C6alkyl, or —(CH2)n-A;
- wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-7 heterocycloalkyl, spiro structures of either of these rings, and bicyclic structures of either of these rings, and n is 0, 1, or 2;
- wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, hydroxy, halo, hydroxyC1-6 alkyl, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, and methylsulfonyl;
- and
- R7 and R8 are the same or different and each is hydrogen, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.
-18. (canceled)
A compound of formula (IV):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is ethynyl or ethyl;
- R1′ is hydrogen or halo;
- R1″ is selected from hydrogen, C2-3alkenyl, C1-3 alkyl, C2-3 alkynyl, halo, and hydroxy;
- R2 is hydrogen;
- R3 is halo;
- R6 is C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, hydroxy-haloC1-6 alkyl, methylsulfonylC1-C6alkyl, or —(CH2)n-A;
- wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-7 heterocycloalkyl, spiro structures of either of these rings, and bicyclic structures of either of these rings, and n is 0, 1, or 2;
- wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, hydroxy, halo, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, and methylsulfonyl;
- and
- R7 and R8 are the same or different and each is hydrogen, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.
-24. (canceled)
A compound of formula (V):
- or a pharmaceutically acceptable salt thereof, wherein:
- Y is O or SO2;
- R1 and R1′ are the same or different and each is hydrogen, halo, C1-4 alkyl, C2-4 alkenyl, C3-6 cycloalkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy;
- R2 is hydrogen;
- R3 is halo;
- R4 and R5 are the same or different and each is hydrogen, C1-4 alkyl, or hydroxy;
- R20 is selected from hydrogen and hydroxyC1-4alkyl;
- R6 is C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, hydroxy-haloC1-6 alkyl, methylsulfonylC1-C6alkyl, or —(CH2)n-A;
- wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-7 heterocycloalkyl, spiro structures of either of these rings, and bicyclic structures of either of these rings, and n is 0, 1, or 2;
- wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, cyano, C3-6 cycloalkylcarbonyl, hydroxy, halo, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, hydroxy C1-4alkyl, and methylsulfonyl;
- and
- R7 and R8 are the same or different and each is hydrogen, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.
-29. (canceled)
A compound of formula (VI):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 and R1′ are the same or different and each is hydrogen, halo, C1-4 alkyl, C3-6 cycloalkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy;
- R2 is hydrogen;
- R3 is halo;
- R4, R5, R4′, and R5′ are the same or different and each is hydrogen, haloC1-4 alkyl, C1-4 alkyl, hydroxy, or hydroxyC1-4alkyl, or, R4′ and R5′, together with the atom to which they are attached, form a five-membered heterocycloalkyl ring optionally substituted with oxo;
- R6 is C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, hydroxy-haloC1-6 alkyl, methylsulfonylC1-C6alkyl, or —(CH2)n-A;
- wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-7 heterocycloalkyl, spiro structures of either of these rings, and bicyclic structures of either of these rings, and n is 0, 1, or 2;
- wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, hydroxy, halo, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, and methylsulfonyl;
- and
- R7 and R8 are the same or different and each is hydrogen, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.
-34. (canceled)
A compound selected from the group consisting of
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.